Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913217 | 0.99 | DUT (0.90) | DUTPDE3A | |
| SCHEMBL913731 | 0.99 | DUT (0.90) | DUTPDE3A | |
| SCHEMBL3080829 | 0.96 | DUT (1.00) | DUTPDE3A | |
| SCHEMBL12268311 | 0.84 | DUT (0.66) | DUTPDE3A | |
| SCHEMBL913645 | 0.77 | DUT (0.70) | DUT | |
| SCHEMBL19359497 | 0.77 | DUT (0.69) | DUT | |
| SCHEMBL30903383 | 0.76 | DUT (0.59) | DUTPDE3A | |
| SCHEMBL12268297 | 0.76 | DUT (0.68) | DUT | |
| SCHEMBL913176 | 0.76 | DUT (0.68) | DUT | |
| SCHEMBL30903389 | 0.75 | DUT (0.58) | DUTPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | DUT 1/4885PDE3A 3325/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | DUT 1/4885PDE3A 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.